Improvement of functioning in patients with schizophrenia: real‑world effectiveness of aripiprazole once‑monthly (REACT study)
Abstract Conclusions:Our work here showed that patients with schizophrenia, treated with AOM in everyday clinical conditions, may experience clinically
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
Abstract Conclusions: Treatment with AOM for patients with schizophrenia appeared effective and safe under real-life conditions. להמשך קריאה Schöttle, D.,
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial
Abstract Importance: Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for
Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia
Abstract Objective Recent-onset schizophrenia (ROS) represents a critical period that can greatly influence the clinical course of schizophrenia. The
Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
Abstract Aim This research aims to compare the efficacy and direct costs of short-acting oral antipsychotics and aripiprazole once-monthly (AOM)
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
Abstract Background: In this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) was
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial
Abstract Objective: To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
Abstract Background With previously established efficacy of aripiprazole once-monthly injectable formulation (AOM) in pre-registration randomized controlled trials, the current
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Abstract Background: In this study, the treatment of schizophrenia patients with aripiprazole once-monthly (AOM) was evaluated under real-life conditions
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
Abstract Objective To evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia. להמשך
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics
Abstract Objective: To assess the effects of aripiprazole once-monthly 400 mg (AOM 400) on clinical symptoms and global improvement in
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
Abstract Objective To directly compare aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs–Carpenter Quality-of-Life Scale (QLS), a validated
Improvement of functioning in patients with schizophrenia: real‑world effectiveness of aripiprazole once‑monthly (REACT study)
Abstract Conclusions:Our work here showed that patients with schizophrenia, treated with AOM in everyday clinical conditions, may experience clinically relevant functional improvements. These
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
Abstract Conclusions: Treatment with AOM for patients with schizophrenia
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial
Abstract Importance: Long-acting injectable antipsychotics (LAIs) can potentially reduce
Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia
Abstract Objective Recent-onset schizophrenia (ROS) represents a critical
Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
Abstract Aim This research aims to compare the efficacy
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
Abstract Background: In this non-interventional study, the functionality
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial
Abstract Objective: To document the acceptability of treatment with
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
Abstract Background With previously established efficacy of aripiprazole
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Abstract Background: In this study, the treatment of
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
Abstract Objective To evaluate long-term safety and effectiveness
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics
Abstract Objective: To assess the effects of aripiprazole once-monthly
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
Abstract Objective To directly compare aripiprazole once-monthly 400 mg (AOM 400)